2020
DOI: 10.1590/s0004-2803.202000000-45
|View full text |Cite
|
Sign up to set email alerts
|

Discontinuation Rates Following a Switch From a Reference to a Biosimilar Biologic in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Abstract: BACKGROUND: Biologics have revolutionized the treatment of inflammatory bowel disease (IBD). However, these drugs had a significant influence on treatment-related costs, which resulted in the development of biosimilars. OBJECTIVE: This systematic review and meta-analysis aimed to evaluate the drug discontinuation rate in the IBD population who switched from originator to biosimilars in real-world switching studies and address potential nocebo effects as reasons for drug discontinuation. METHODS: Medline (… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 10 publications
(5 citation statements)
references
References 56 publications
0
5
0
Order By: Relevance
“…The most common causes of discontinuation were loss of response (5%) and adverse events (7%). 13 …”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The most common causes of discontinuation were loss of response (5%) and adverse events (7%). 13 …”
Section: Discussionmentioning
confidence: 99%
“…The most common causes of discontinuation were loss of response (5%) and adverse events (7%). 13 This survey had several limitations. It was selfselective, only available online in a European website in eight languages (including Portuguese), which may have contributed to the low access of Brazilians to the questionnaire.…”
Section: Quality Of Information and Communication On Biosimilars In Brazilian Ibd Patientsmentioning
confidence: 99%
“… 52 Queiroz et al . 53 conducted a meta‐analysis of 30 observational studies involving a total of 3,594 patients with IBD to examine the impact of an innovator to biosimilar switch on discontinuation rates over time. All studies in the dataset included a minimum post‐switch follow‐up of > 6 months or 3 infusions.…”
Section: Challenges For Biosimilar Adoptionmentioning
confidence: 99%
“…As such, the nocebo effect may play an important role in the higher‐than expected discontinuation rates reported in patients with immune‐mediated disease who switched to the biosimilar CT‐P13 after being stabilized on an innovator treatment 52 . Queiroz et al 53 . conducted a meta‐analysis of 30 observational studies involving a total of 3,594 patients with IBD to examine the impact of an innovator to biosimilar switch on discontinuation rates over time.…”
Section: Challenges For Biosimilar Adoptionmentioning
confidence: 99%
“…The nocebo effect may have an important impact on an increased discontinuation rate after switching in the absence of patient symptomatology [73,75]. Real-world studies of anti-TNF-α agents show higher discontinuation rates in patients switched to biosimilars for non-medical reasons than in historical cohorts maintained on innovators [8,71,76].…”
Section: Psychosocial Aspects and The Nocebo Effectmentioning
confidence: 99%